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Introduction
Mevalonate kinase deficiency-associated periodic fever
syndrome is a systemic autoinflammatory disease caused
by mutations in the mevalonate kinase gene (MVK),
previously named “hyper-IgD syndrome” due to its char-
acteristic increase in serum IgD level. The patients suffer
recurrent fever attacks every 2-8 weeks beginning from
infancy, often precipitated by immunizations, infections
or emotional stress. Fever lasts 2-7 days and can be
accompanied by malaise, headache, diarrhea, abdominal
pain, vomiting, skin rashes, arthralgia, arthritis, tender
lymphadenopathy and hepatosplenomegaly. Fever attacks
usually respond to the administration of steroids. How-
ever, increasing frequency of fever episodes with steroid
use and the natural chronic disease course may require a
continuous long-term treatment. Colchicine, cyclospor-
ine, thalidomide and statins are not effective. A TNF-a
blocking agent etanercept and IL-1 blocking agents ana-
kinra and canakinumab have been demonstrated to
reduce the frequency of fever attacks in MKD. The
course and severity of the disease may be quite different.
Objectives
We report three cases with HIDS, who have separate
clinical findings and treatment strategies.
Methods
Patient 1 was a 12-years-old girl suffered from recurrent
fever, abdominal pain, arthritis of the fingers, and cervical
lymphadenopathy. The attacks started when she was fif-
teen months old. Each attack lasted for about a week, 2-
3 times annually. She did not have a MEFV mutation.
Genetic analysis of the MVK gene revealed two missense
mutations: p.V377 on exon 11 and c.38_39 ins TCTG
frameshift on exon 2. On follow-up, she had 2 mild attacks
in the last year; one of them was treated with a single high
dose oral prednisone.
Patient 2 was a 17-months-old boy suffered from peri-
odic fever since two months following birth once or
twice a month, lasting for 2-4 days. He had diarrhea and
cervical lymphadenopathy during attacks. The heterozy-
gous V726A variant of MEFV was detected. He was put
on colchicine therapy; however he did not respond
despite 6 months of therapy. Further genetic analysis
revealed two mutations on MVK gene (Exon 8. c.803T>C
(p.268I>T), and Exon 10 c.1129 G>A (p.377V>I). Simvas-
tatin, etanercept and anakinra were not effective. Corti-
costeroid shortened the duration of fever during attacks,
however; failed to lower the frequency of attacks. He had
a dramatic response to canakinumab.
Patient 3 was the sister of patient 3. Parents were non-
consanguineous. She suffered from recurrent fever, diar-
rhea and cervical lymphadenopathy every month since
3 months of age. She had the same mutations of her
brother. Besides, the heterozygous E148Q variant of
MEFV was detected. She is given corticosteroid during
attacks regarding the parents refuse to use IL-1 blocker
because of her small age (2 years old).
Results
We speculate that the more severe and drug-resistant
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